Skip to main content
Equibles
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc.

Track LCTX — free

Use LCTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LCTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.07 +0.01 (+0.94%) At close · Aug 14
Customer concentration — top 2 customers 92% of revenue

2 customers — 92% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”

One customer — 92% of revenue (the year ended December 31, 2024)

“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
View the 10-K filed Mar 5, 2026
Market Cap
$270.61M
Shares
252.91M

Lineage Cell Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Lineage Cell Therapeutics, Inc. (LCTX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲32.1% $3.00M −$6.07M '22 Q3 22-11-10 ▲64% $1.92M −$6.35M '22 Q4 23-03-09 ▼54.4% $2.39M −$4.37M '23 Q1 23-05-11 ▼29.2% $3.23M −$5.23M '23 Q2 23-08-10 ▼58.4% $1.25M −$7.11M '23 Q3 23-11-09 ▲9% $2.09M −$4.78M '23 Q4 24-03-07 ▼39.5% $1.44M −$6.54M '24 Q1 24-05-09 ▼56.3% $1.41M −$5.76M '24 Q2 24-08-08 ▲203.3% $3.78M −$3.03M '24 Q3 24-11-14 ▲37.4% $2.87M −$3.27M '24 Q4 25-03-10 ▲4% $1.50M −$4.14M '25 Q1 25-06-02 ▲96.4% $2.77M −$30.46M '25 Q2 25-08-12 ▼2.6% $3.68M −$29.78M '25 Q3 25-11-06 ▲130.4% $6.61M $851,000 '25 Q4 26-03-05 ▲14.8% $1.73M −$4.81M '26 Q1 26-05-12 LATEST ▼61.3% $1.07M $1.48M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Second Quarter 2026 Financial Results Earnings Call
Revenue
$1.07M
▼ 61.3% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Lineage Cell Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone Pipeline diversification and platform leverage Manufacturing philosophy and process risk Clinical trial execution / site expansion
Revenue
$1.73M
▲ 14.8% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Lineage Cell Therapeutics, Inc. Q4 FY2025 Earnings Call
Positive tone Manufacturing Platform (Alloscope) Israel Operations and Employee Safety Pipeline Expansion Beyond Oncology
Revenue
$6.61M*
▲ 130.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Lineage Cell Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone Partnership with Roche/Genentech Manufacturing and cost control Islet cell / Type 1 diabetes initiative
Revenue
$3.68M
▼ 2.6% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Lineage Cell Therapeutics, Inc. Q2 FY2025 Earnings Call
Positive tone Spinal cord injury (OPC1) clinical program Roche/Genentech partnership and Phase 2A trial Manufacturing and platform technology
Revenue
$2.77M
▲ 96.4% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-06-02
Lineage Cell Therapeutics, Inc. Q1 FY2025 Earnings Call
Positive tone OpRegen Phase 2a GAlette Study OPC1 spinal cord injury dose study Surgical delivery optimization
Revenue
$1.50M
▲ 4% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Lineage Cell Therapeutics, Inc. Q4 FY2024 Earnings Call
Revenue
$2.87M*
▲ 37.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Lineage Cell Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone OpRegen / Dry AMD program (partnered with Roche/Genentech) FDA interactions and OPC1 / DOSED study startup Pipeline expansion and hearing loss (ANP1) program
Revenue
$3.78M
▲ 203.3% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Lineage Cell Therapeutics, Inc. Q2 FY2024 Earnings Call
Revenue
$1.41M
▼ 56.3% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Lineage Cell Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone OpRegen Phase I/IIa 24-month data Genentech/Roche partnership and services agreement Dry AMD commercial market
Revenue
$1.44M
▼ 39.5% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Lineage Cell Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone OpRegen dry AMD program Roche/Genentech partnership OPC1 spinal cord program and IND clearance
Revenue
$2.09M
▲ 9% YoY
Diluted EPS
$-0.03
Gross margin
87.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Lineage Cell Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$1.25M
▼ 58.4% YoY
Diluted EPS
$-0.04
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Lineage Cell Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$3.23M
▼ 29.2% YoY
Diluted EPS
$-0.03
Gross margin
96.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Lineage Cell Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$2.39M
▼ 54.4% YoY
Diluted EPS
$-0.03
Gross margin
95.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Lineage Cell Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$1.92M
▲ 64% YoY
Diluted EPS
$-0.03
Gross margin
94.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Lineage Cell Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$3.00M
▲ 32.1% YoY
Diluted EPS
$-0.04
Gross margin
92.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Lineage Cell Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$4.55M
▲ 789.3% YoY
Diluted EPS
$-0.04
Gross margin
95.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Lineage Cell Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$5.24M
▲ 1239.4% YoY
Diluted EPS
$-0.04
Gross margin
96.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Lineage Cell Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$1.17M
▲ 229% YoY
Gross margin
82.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Lineage Cell Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$2.27M
▲ 297.5% YoY
Diluted EPS
$-0.05
Gross margin
56.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Lineage Cell Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$512,000
▲ 32.6% YoY
Diluted EPS
$-0.03
Gross margin
75.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Lineage Cell Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$391,000
▼ 23.9% YoY
Diluted EPS
$-0.01
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Lineage Cell Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$355,000
▼ 71.4% YoY
Gross margin
67.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Lineage Cell Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$571,000
▲ 0.7% YoY
Diluted EPS
$-0.05
Gross margin
82.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Lineage Cell Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$386,000
▼ 50.4% YoY
Diluted EPS
$-0.04
Gross margin
80.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Lineage Cell Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$514,000
▼ 44.6% YoY
Diluted EPS
$-0.06
▼ 120% YoY
Gross margin
81.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Lineage Cell Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$1.24M
▲ 63.7% YoY
Gross margin
90.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 876343 CUSIP 53566P109 13F (30d) 124 filings 123 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)